Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Dicerna Pharmaceuticals (DRNA) PT Raised to $20 at SunTrust Robinson Humphrey
September 5, 2018 9:48 AM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $15.00) while maintaining a Buy rating after the company reported PoC data from the ongoing Phase I PHYOX study in primary hyperoxaluria I and... More
